NCT03982381View on ClinicalTrials.gov

SGLT2 Inhibitor or Metformin As Standard Treatment of Early Stage Type 2 Diabetes

PHASE4Active, not recruitingINTERVENTIONAL
Enrollment

2,067

Participants

Timeline

Start Date

September 5, 2019

Primary Completion Date

October 15, 2025

Study Completion Date

October 15, 2025

Conditions
Type 2 Diabetes
Interventions
DRUG

Metformin

Active comparator

DRUG

Dapagliflozin 10 MG

Experimental treatment

Trial Locations (1)

75185

Uppsala University Hospital, Uppsala

All Listed Sponsors
collaborator

Uppsala University Hospital

OTHER

collaborator

Swedish Healthcare Regions

UNKNOWN

collaborator

National Board of Health and Welfare, Sweden

OTHER_GOV

collaborator

The Swedish National Diabetes Register

UNKNOWN

lead

Uppsala University

OTHER